ConvaTec Group to acquire Triad Life Sciences for $450m.

ConvaTec Group, a global medical solutions company focused on the management of chronic conditions, agreed to acquire Triad Life Sciences, a US-focused medical device company that develops biologically-derived innovative products to address unmet clinical needs in surgical wounds, chronic wounds and burns, for $450m. "Today’s announcement marks another successful step in our strategic intent of pivoting to sustainable and profitable growth. This transaction will strengthen our Wound Care business and enable ConvaTec to enter the rapidly growing wound biologics segment. Triad Life Sciences has innovative and differentiated products and an exciting pipeline which is consistent with our vision – Pioneering trusted medical solutions to improve the lives we touch. We are delighted that Russ and the team have decided to join ConvaTec," Karim Bitar, ConvaTec Group CEO.